The Congress should change Part D’s coverage-gap discount to:
- require manufacturers of biosimilar products to pay the coverage-gap discount by including biosimilars in the definition of “applicable drugs” and
- exclude biosimilar manufacturers’ discounts in the coverage gap from enrollees’ true out-of-pocket spending.